Digital Look

Welcome to Digital Look++,
you are not logged in

Indivior (INDV)

Pharma and Biotech

837.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Sep-24	Q3	307.00	(1.00)	3.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	785.00	180.00	120.00¢	2.0	n/a	-35%	n/a	0.0%
31-Dec-20	647.00	(173.00)	40.00¢	17.1	n/a	-67%	n/a	0.0%
31-Dec-21	791.00	190.00	19.20¢	84.1	n/a	-52%	n/a	0.0%
31-Dec-22	901.00	(95.00)	(38.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	1,093.00	1.00	1.00¢	1,489.8	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	1,161.40	246.53	131.35p	6.4	0.0	+16,497%	n/a	0.0%
31-Dec-25	1,119.22	279.65	137.39p	6.1	1.3	+5%	n/a	0.0%
31-Dec-26	1,211.77	337.77	170.25p	4.9	0.2	+24%	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	2.15	2.15	312.34	3.37

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.